Lupus & antiphospholipid syndrome
Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort
Main finding · Prolonged remissionResult — go to the resultPS-adjusted OR 2.50 95% CI 1.04–623Authors' conclusion
This study supports the use of MP to induce prolonged remission in patients with SLE, particularly in those with moderate and severe activity. The extended use of HCQ also contributes to achieve prolonged remission.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) in the Lupus-Cruces-Bordeaux inception cohort
- Participants
- 233 patients
- Exposure
- Methylprednisolone pulses (MP) during the first year after SLE diagnosis vs no MP
- Outcome
- Prolonged remission (during five consecutive yearly visits)
Methodological detailspropensity score analysis, logistic regression with propensity score (PS) and other therapeutic covariates, routine clinical care data
- Propensity score analysis
- Logistic regression with PS and other therapeutic covariates
- Routine clinical care data
Main finding
Prolonged remission
PS-adjusted OR
2.50
95% CI 1.04–623
P = 0.042
As reported in the abstract
- Prolonged remission achieved, whole cohort
- 132 patients (57%)
Observational data: associations, not effects.
Further findings
Average prednisone dose during first year, moderate activity (subgroup)
P = 0.017
Average prednisone dose during first year, severe activity (subgroup)
P = 0.015
Other predictors of prolonged remission
- Odds increased by longer-term use of hydroxychloroquine (HCQ) and decreased by higher initial doses of prednisone
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →